INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential securities fraud and unlawful business practices following disappointing Phase 3 study results for its treatment setrusumab, which led to a significant drop in stock price [1][3][4]. Group 1: Company Performance - Mereo announced results from two Phase 3 studies for setrusumab, a treatment aimed at conditions affecting bone metabolism [3]. - Neither study met the primary endpoints of reducing the annualized clinical fracture rate compared to placebo or bisphosphonates, although both achieved secondary endpoints related to improvements in bone mineral density with strong statistical significance [3]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, a decrease of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Mereo investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].